Network congestion

Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®

Retrieved on: 
Thursday, February 8, 2024

Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.

Key Points: 
  • Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.
  • Previously published three-month results of the randomized controlled trial demonstrated that treatment with VivAer was safe and superior to a sham procedure.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240208997581/en/
    Two-year outcomes from the VATRAC trial published in Rhinology Journal confirm that treatment with VivAer® resulted in significant and lasting improvements in nasal obstruction symptoms.
  • This publication adds to a deep dossier of clinical evidence for VivAer, with three separate studies now confirming multi-year durability.

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2023 and provided a corporate update.  

Key Points: 
  • The Company plans to submit results of the BEACON study for presentation at an upcoming medical meeting.
  • In August 2023, Lyra announced completion of enrollment in the pivotal Phase 3 ENLIGHTEN I clinical trial.
  • Cash, cash equivalents and short-term investments as of September 30, 2023 were $102.6 million, compared with $116.2 million at June 30, 2023.
  • Net loss for the quarter ended September 30, 2023 was $15.7 million compared to $14.8 million for the same period in 2022.

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Retrieved on: 
Tuesday, September 12, 2023

WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.

Key Points: 
  • WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.
  • The study met its primary safety endpoint, with no serious adverse events observed.
  • Topline results from the BEACON study of LYR-220 will be presented at the American Rhinologic Society (ARS) 69th Annual Meeting on September 30, 2023, in Nashville, TN.
  • ET to discuss the topline results of the BEACON study.

Aerin Medical Announces New Positive Two-Year Results from VivAer® AERWAY Study

Retrieved on: 
Thursday, July 13, 2023

Results featured in Laryngoscope Investigative Otolaryngology showed a significant and long-term improvement in NAO symptom burden.

Key Points: 
  • Results featured in Laryngoscope Investigative Otolaryngology showed a significant and long-term improvement in NAO symptom burden.
  • A non-invasive technology developed by Aerin Medical Inc., VivAer uses patented, temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction.
  • The AERWAY study, a prospective, multi-center trial, followed patients after a single treatment session with VivAer and collected two-year outcomes for 91 patients.
  • “The positive two-year outcomes from the AERWAY trial build upon published VivAer clinical results, including superior symptom improvements in a randomized controlled trial and a four-year study showing long-term durability of a single VivAer treatment,” said Matt Brokaw, CEO of Aerin Medical.

Aerin Medical Supports AAO-HNS Position Recognizing Nasal Valve Repair as a Distinct Procedure that Improves Nasal Obstruction Symptoms

Retrieved on: 
Tuesday, April 18, 2023

The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.” The Academy notes that office-based techniques, including radiofrequency treatment, can stabilize the nasal valve, optimize nasal valve collapse (NVC) patient outcomes, and be performed either as a standalone procedure or in combination with other procedures to potentially avoid multiple surgeries.

Key Points: 
  • The statement recognizes nasal valve repair as “a distinct surgical procedure that can improve nasal obstruction symptoms for appropriately selected patients.” The Academy notes that office-based techniques, including radiofrequency treatment, can stabilize the nasal valve, optimize nasal valve collapse (NVC) patient outcomes, and be performed either as a standalone procedure or in combination with other procedures to potentially avoid multiple surgeries.
  • View the full release here: https://www.businesswire.com/news/home/20230418005388/en/
    New guidance from the American Academy of Otolaryngology-Head and Neck Surgery notes that radiofrequency treatments can be used to stabilize the nasal valve and optimize nasal valve collapse (NVC) patient outcomes.
  • VivAer, a non-invasive technology developed by Aerin Medical, uses temperature-controlled radiofrequency energy to provide long-term relief from nasal obstruction caused by NVC.
  • “Nasal airway obstruction is one of the primary reasons a patient visits an ENT physician, and we hope that this enables ENTs to treat nasal valve collapse with minimally invasive solutions when it contributes to nasal obstruction.”

ENT Specialty Partners Announces Opening of Austin ENT & Allergy

Retrieved on: 
Monday, April 17, 2023

AUSTIN, Texas, April 17, 2023 /PRNewswire/ -- ENT Specialty Partners (ESP), one of the largest independent ear, nose, and throat practices in the country, announces the opening of Austin ENT & Allergy at 12201 Renfert Way, Suite 245, Austin, TX 78758 on the campus of St. David's North Austin Medical Center.

Key Points: 
  • AUSTIN, Texas, April 17, 2023 /PRNewswire/ -- ENT Specialty Partners (ESP), one of the largest independent ear, nose, and throat practices in the country, announces the opening of Austin ENT & Allergy at 12201 Renfert Way, Suite 245, Austin, TX 78758 on the campus of St. David's North Austin Medical Center.
  • "I'm honored to be a part of Austin ENT & Allergy to bring a quality, personalized approach to ENT care for patients in the North Austin community," said Dr. Myhill.
  • Patients may schedule appointments at Austin ENT & Allergy through their website, entatx.com or by calling (512) 277-7500, Monday through Friday, 8:00 a.m. – 5:00 p.m.
  • The ENT Specialty Partners practice community now includes 28 ENT physicians, 10 advanced practice providers, and 22 audiologists/hearing specialists.

Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis

Retrieved on: 
Tuesday, November 22, 2022

Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.

Key Points: 
  • Idiopathic rhinitis is a medical disorder characterized by a collection of nasal symptoms that resemble nasal allergies and hay fever (allergic rhinitis) but are not caused by a known cause like allergens or infectious triggers.
  • Idiopathic rhinitis features an overexpression of TRPV1 in the nasal mucosa giving rise to nasal obstruction, rhinorrhoea (colloquially: a runny nose), and/or sneezing.
  • Hyloris treatment approach is to activate and depolarize TRPV1 receptors leading to restoration of a normal function of the nasal mucosa.
  • Stijn Van Rompay, Chief Executive Officer of Hyloris,commented: We are pleased to announce another value-added product candidate to add to our portfolio of programs.

Aerin Medical Announces CMS Set to Implement New CPT® Code for Temperature-Controlled Radiofrequency Repair of Nasal Valve Collapse

Retrieved on: 
Wednesday, November 16, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221116005226/en/
    CMS is set to implement a new CPT code that includes the use of VivAer to repair nasal valve collapse in the office and outpatient surgical settings.
  • VivAer is a non-invasive, temperature-controlled radiofrequency technology that provides long-term relief from nasal obstruction.
  • CPT code 30469, repair of NVC with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling, was established by the American Medical Association (AMA) describing use of VivAer for this procedure.
  • For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook , Twitter , Instagram , LinkedIn and YouTube .